BioWorld

Feb. 12, 2002

United Therapeutics Receives Remodulin Approvable Letter

Following receipt of an approvable letter from the FDA, United Therapeutics Corp. said its orphan drug for pulmonary arterial hypertension should reach the market sometime in the next two months. (BioWorld Today) Read More

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

One Of 40 Myosin Proteins In Mammalian Body Led Mice To Key Hearing-Mechanism Clue

Inhibitex Closing $41M Round To Fund Product Development

CytRx, Global Genomics Merging In Deal Worth Up To $6.28M

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...